{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:00:44Z","timestamp":1791205244957,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Double Thousand Talents Program of Jiangxi Province","award":["jxsq2019101021"],"award-info":[{"award-number":["jxsq2019101021"]}]},{"name":"the Key Laboratory Project of Neurological Diseases in Jiangxi Province","award":["2024SSY06072"],"award-info":[{"award-number":["2024SSY06072"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with myasthenia gravis (MG) are prone to resulting in a significant psychological burden. This study aims to investigate the condition of fear of progression (FoP) and identify factors associated with FoP among MG patients. This cross-sectional study included 83 patients with MG admitted to the First Affiliated Hospital of Nanchang University from January to November 2024. Data were collected through clinical records and questionnaires, including demographic details, disease duration, comorbidities, current drug regimen, and the fear of progression questionnaire-short form (FoP-Q-SF). The simplified fear of progression scale score for 83 MG patients was 31.36\u2009\u00b1\u200910.22. Among these participants, 38.6% exhibited dysfunction FoP. There was no significant difference concerning age, marital status, course of the disease, crisis of MG, STAI score, and TAI score in the total score of fear of disease progression in MG patients. However, gender, progress of MG and MGFA classification were positively correlated with the fear of progression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05), which was statistically significant. Furthermore, gender and disease progression were identified as factors influencing FoP in MG patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). FoP among MG patients varies according to their socio-demographic and clinical characteristics. Gender and progress history of MG are associated with Fop.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-11806-0","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T21:55:33Z","timestamp":1752875733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A cross-sectional study on fear of progression in patients with myasthenia gravis"],"prefix":"10.1038","volume":"15","author":[{"given":"Si","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"11806_CR1","doi-asserted-by":"publisher","unstructured":"CherukupallyKR, KodjoK, Ogunsakin, O., Olayinka, O. & FouronP Comorbid depressive and anxiety symptoms in a patient with myasthenia Gravis. Case Rep. Psychiatry. 2020 (8967818). https:\/\/doi.org\/10.1155\/2020\/8967818 (2020).","DOI":"10.1155\/2020\/8967818"},{"issue":"10","key":"11806_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol.14(10), 1023\u20131036. https:\/\/doi.org\/10.1016\/s1474-4422(15)00145-3 (2015).","journal-title":"Lancet Neurol."},{"key":"11806_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin, S., Frenkian-Cuvelier, M. & Eymard, B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J. Autoimmun. 143\u2013148. https:\/\/doi.org\/10.1016\/j.jaut.2014.01.003 (2014).","journal-title":"J. Autoimmun."},{"issue":"7","key":"11806_CR4","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","volume":"45","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano, V. et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol. Sciences: Official J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol. 45 (7), 3481\u20133494. https:\/\/doi.org\/10.1007\/s10072-024-07368-0 (2024).","journal-title":"Neurol. Sciences: Official J. Italian Neurol. Soc. Italian Soc. Clin. Neurophysiol."},{"issue":"6","key":"11806_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00023210-200721060-00004","volume":"21","author":"IB Kulaksizoglu","year":"2007","unstructured":"Kulaksizoglu, I. B. Mood and anxiety disorders in patients with myasthenia gravis: Aetiology, diagnosis and treatment. CNS Drugs21(6), 473\u2013481. https:\/\/doi.org\/10.2165\/00023210-200721060-00004 (2007).","journal-title":"CNS Drugs"},{"issue":"4","key":"11806_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1176\/jnp.12.4.499","volume":"12","author":"RH Paul","year":"2000","unstructured":"Paul, R. H., Cohen, R. A., Goldstein, J. M. & Gilchrist, J. M. Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis. J. Neuropsychiatry Clin. Neurosci.12(4), 499\u2013501. https:\/\/doi.org\/10.1176\/jnp.12.4.499 (2000).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"45","key":"11806_CR7","first-page":"3176","volume":"90","author":"L Qiu","year":"2010","unstructured":"Qiu, L. et al. [Study of incidence and correlation factors of depression, anxiety and insomnia in patients with myasthenia gravis]. Zhonghua Yi Xue Za Zhi. 90 (45), 3176\u20133179 (2010).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"5","key":"11806_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/00207454.2015.1038712","volume":"126","author":"Y Yang","year":"2016","unstructured":"Yang, Y. et al. Quality of life in 188 patients with myasthenia gravis in China. Int. J. Neurosci.126(5), 455\u2013462. https:\/\/doi.org\/10.3109\/00207454.2015.1038712 (2016).","journal-title":"Int. J. Neurosci."},{"issue":"3","key":"11806_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1055\/s-2003-40094","volume":"42","author":"A Dankert","year":"2003","unstructured":"Dankert, A. et al. [Fear of progression in patients with cancer, diabetes mellitus and chronic arthritis]. Die Rehabilit. 42 (3), 155\u2013163. https:\/\/doi.org\/10.1055\/s-2003-40094 (2003).","journal-title":"Die Rehabilit."},{"key":"11806_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1222798","volume":"14","author":"JL He","year":"2023","unstructured":"He, J. L. et al. Fear of disease progression among breast cancer patients in China: A meta-analysis of studies using the fear of progression questionnaire short form. Front. Psychol.14, 1222798. https:\/\/doi.org\/10.3389\/fpsyg.2023.1222798 (2023).","journal-title":"Front. Psychol."},{"issue":"6","key":"11806_CR11","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00520-014-2516-5","volume":"23","author":"A Hinz","year":"2015","unstructured":"Hinz, A., Mehnert, A., Ernst, J., Herschbach, P. & Schulte, T. Fear of progression in patients 6 months after cancer rehabilitation-a- validation study of the fear of progression questionnaire FoP-Q-12. Support. Care Cancer23(6), 1579\u20131587. https:\/\/doi.org\/10.1007\/s00520-014-2516-5 (2015).","journal-title":"Support. Care Cancer"},{"key":"11806_CR12","doi-asserted-by":"publisher","first-page":"102600","DOI":"10.1016\/j.ejon.2024.102600","volume":"70","author":"M Xiong","year":"2024","unstructured":"Xiong, M. et al. The impact of fear of cancer recurrence on the quality of life of breast cancer patients: A longitudinal study of the mediation effect of cortisol and hope. Eur. J. Oncol. Nursing: Official J. Eur. Oncol. Nurs. Soc. 70, 102600. https:\/\/doi.org\/10.1016\/j.ejon.2024.102600 (2024).","journal-title":"Eur. J. Oncol. Nursing: Official J. Eur. Oncol. Nurs. Soc."},{"issue":"3","key":"11806_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/08964289.2011.605399","volume":"37","author":"T Zimmermann","year":"2011","unstructured":"Zimmermann, T., Herschbach, P., Wessarges, M. & Heinrichs, N. Fear of progression in partners of chronically ill patients. Behav. Med. (Washington DC). 37 (3), 95\u2013104. https:\/\/doi.org\/10.1080\/08964289.2011.605399 (2011).","journal-title":"Behav. Med. (Washington DC)"},{"key":"11806_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-170","volume":"11","author":"M Donald","year":"2013","unstructured":"Donald, M. et al. Mental health issues decrease diabetes-specific quality of life independent of glycaemic control and complications: Findings from Australia\u2019s living with diabetes cohort study. Health Qual. Life Outcomes11, 170. https:\/\/doi.org\/10.1186\/1477-7525-11-170 (2013).","journal-title":"Health Qual. Life Outcomes"},{"key":"11806_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jpsychores.2017.12.010","volume":"105","author":"J Grammes","year":"2018","unstructured":"Grammes, J. et al. Fear of hypoglycemia in patients with type 2 diabetes: The role of interoceptive accuracy and prior episodes of hypoglycemia. J. Psychosom. Res.105, 58\u201363. https:\/\/doi.org\/10.1016\/j.jpsychores.2017.12.010 (2018).","journal-title":"J. Psychosom. Res."},{"key":"11806_CR16","doi-asserted-by":"publisher","unstructured":"Gong, M., Dong, H., Tang, Y., Huang, W. & Lu, F. Effects of aromatherapy on anxiety: A meta-analysis of randomized controlled trials. J. Affect. Disorders 2020, 274:1028\u20131040. https:\/\/doi.org\/10.1016\/j.jad.2020.05.118","DOI":"10.1016\/j.jad.2020.05.118"},{"issue":"3","key":"11806_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.13109\/zptm.2006.52.3.274","volume":"52","author":"A Mehnert","year":"2006","unstructured":"Mehnert, A., Herschbach, P., Berg, P., Henrich, G. & Koch, U. [Fear of progression in breast cancer patients\u2013validation of the short form of the fear of progression questionnaire (FoP-Q-SF)]. Z. Psychosomat. Med. Psychother. 52 (3), 274\u2013288. https:\/\/doi.org\/10.13109\/zptm.2006.52.3.274 (2006).","journal-title":"Z. Psychosomat. Med. Psychother."},{"issue":"1","key":"11806_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000254903","volume":"79","author":"P Herschbach","year":"2010","unstructured":"Herschbach, P. et al. Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychother. Psychosom.79(1), 31\u201338. https:\/\/doi.org\/10.1159\/000254903 (2010).","journal-title":"Psychother. Psychosom."},{"issue":"4","key":"11806_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.numecd.2017.01.006","volume":"27","author":"L Indelicato","year":"2017","unstructured":"Indelicato, L. et al. Psychological distress, self-efficacy and glycemic control in type 2 diabetes. Nutr. Metabolism Cardiovasc. Diseases: NMCD. 27 (4), 300\u2013306. https:\/\/doi.org\/10.1016\/j.numecd.2017.01.006 (2017).","journal-title":"Nutr. Metabolism Cardiovasc. Diseases: NMCD"},{"issue":"7","key":"11806_CR20","doi-asserted-by":"publisher","first-page":"e9184","DOI":"10.7759\/cureus.9184","volume":"12","author":"C Law","year":"2020","unstructured":"Law, C., Flaherty, C. V. & Bandyopadhyay, S. A review of psychiatric comorbidity in myasthenia Gravis. Cureus 12 (7), e9184. https:\/\/doi.org\/10.7759\/cureus.9184 (2020).","journal-title":"Cureus"},{"key":"11806_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.910145","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Predictors of fear of diabetes progression: A multi-center cross-sectional study for patients self-management and healthcare professions education. Front. Public Health10, 910145. https:\/\/doi.org\/10.3389\/fpubh.2022.910145 (2022).","journal-title":"Front. Public Health"},{"issue":"1","key":"11806_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12912-024-02552-1","volume":"23","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Fear of progression in patients with acute myocardial infarction: A cross-sectional study. BMC Nurs.23(1), 866. https:\/\/doi.org\/10.1186\/s12912-024-02552-1 (2024).","journal-title":"BMC Nurs."},{"issue":"9","key":"11806_CR23","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1007\/s00520-019-04665-9","volume":"27","author":"S Goebel","year":"2019","unstructured":"Goebel, S. & Mehdorn, H. M. Fear of disease progression in adult ambulatory patients with brain cancer: prevalence and clinical correlates. Supportive Care Cancer: Official J. Multinational Association Supportive Care Cancer. 27 (9), 3521\u20133529. https:\/\/doi.org\/10.1007\/s00520-019-04665-9 (2019).","journal-title":"Supportive Care Cancer: Official J. Multinational Association Supportive Care Cancer"},{"key":"11806_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1478-4505-11-31","volume":"11","author":"HT Kankeu","year":"2013","unstructured":"Kankeu, H. T., Saksena, P., Xu, K. & Evans, D. B. The financial burden from non-communicable diseases in low- and middle-income countries: A literature review. Health Res. Policy Syst.11, 31. https:\/\/doi.org\/10.1186\/1478-4505-11-31 (2013).","journal-title":"Health Res. Policy Syst."},{"issue":"6","key":"11806_CR25","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer, S. et al. Burden of disease in myasthenia gravis: Taking the patient\u2019s perspective. J. Neurol.269(6), 3050\u20133063. https:\/\/doi.org\/10.1007\/s00415-021-10891-1 (2022).","journal-title":"J. Neurol."},{"issue":"5","key":"11806_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mus.27397","volume":"64","author":"KL Gable","year":"2021","unstructured":"Gable, K. L. & Hobson-Webb, L. D. What is the significance of gender difference in myasthenia gravis?. Muscle Nerve64(5), 515\u2013516. https:\/\/doi.org\/10.1002\/mus.27397 (2021).","journal-title":"Muscle Nerve"},{"issue":"1","key":"11806_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang, L., Zhang, Y. & He, M. Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol.17(1), 77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7 (2017).","journal-title":"BMC Neurol."},{"issue":"1","key":"11806_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke, C. et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia Gravis patients. J. Neuroinflamm. 19 (1), 89. https:\/\/doi.org\/10.1186\/s12974-022-02448-4 (2022).","journal-title":"J. Neuroinflamm."},{"key":"11806_CR29","doi-asserted-by":"publisher","unstructured":"Iacono, S. et al. Frequency and correlates of mild cognitive impairment in myasthenia Gravis. Brain Sci. 13 (2). https:\/\/doi.org\/10.3390\/brainsci13020170 (2023).","DOI":"10.3390\/brainsci13020170"},{"issue":"6","key":"11806_CR30","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.genhosppsych.2014.08.006","volume":"36","author":"A Dinkel","year":"2014","unstructured":"Dinkel, A., Kremsreiter, K., Marten-Mittag, B. & Lahmann, C. Comorbidity of fear of progression and anxiety disorders in cancer patients. Gen. Hosp. Psychiatry. 36 (6), 613\u2013619. https:\/\/doi.org\/10.1016\/j.genhosppsych.2014.08.006 (2014).","journal-title":"Gen. Hosp. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11806-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11806-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11806-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:02:15Z","timestamp":1753264935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11806-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11806"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-11806-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of First Affiliated Hospital of Nanchang University with approval number AF-SG-03-2.1-IIT.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The participants provided their written informed consent to participate in this study. Written informed consent has been obtained from the patients to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}],"article-number":"26181"}}